SPAGO: Sirolimus Paclitaxel Angiographic Gain Objective
A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 140 participants.
Also called NCT06373601
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 140 participants
- Registry
-
NCT06373601
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Italy
- Registry status
- Recruiting
Technical summary
Registry record NCT06373601. Randomized; no masking; primary purpose treatment. Start 2024-09-05 (actual); primary completion 2027-08-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- SPAGO: Sirolimus Paclitaxel Angiographic Gain Objective
- Acronym
- SPAGO
- Condition
- Coronary Artery Disease
- Condition
- Stenosis Coronary
- Condition
- Coronary Artery Lesion
- Condition
- Percutaneous Coronary Intervention
- Intervention (Device)
- sirolimus-eluting balloon (Selution)
- Intervention (Device)
- paclitaxel-eluting balloon (SeQuent Please Neo)
- Lead sponsor
- Fondazione Evidence per Attività e Ricerche Cardiovascolari ONLUS
Record details
- Record id
cardio:ct-nct06373601- Content hash
9a0524cfe5ffb8c9453132a6ab0fa659dd438fbe3e65f49cbc730e19de1115f1